Annals of Hematology最新文献

{"title":"Secondary neoplasms in mycosis fungoides: evaluating risk factors and phototherapy impact in a comparative study.","authors":"Ayda Acar, Ayris Ozturk, Gunseli Ozturk, Ilgen Ertam Sagduyu, Bengu Gerceker Turk, Banu Yaman, Taner Akalın","doi":"10.1007/s00277-025-06442-7","DOIUrl":"https://doi.org/10.1007/s00277-025-06442-7","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IGH/IGK gene rearrangement in the diagnosis of B-cell non-Hodgkin lymphoma: experience from three centers.","authors":"Ke Yang, Zhizhong Wang, Beibei Xin, Yunhang Li, Jiuzhou Zhao, Rui Sun, Weizhen Wang, Dongxu Chen, Chengzhi Zhao, Yongjun Guo, Jie Ma, Bing Wei","doi":"10.1007/s00277-025-06452-5","DOIUrl":"https://doi.org/10.1007/s00277-025-06452-5","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.","authors":"Jens Panse, Bing Han, Jaroslav Cermak, Fernando Ataulfo Gonzalez Fernandez, Akihiko Gotoh, Austin G Kulasekararaj, Olena Kyselova, Fahri Sahin, Phillip Scheinberg, Hubert Schrezenmeier, Nicole Straetmans, Yasutaka Ueda, Alice C Chang, Brittany Gentile, Jennifer Stefani, Marianne Uguen, Alexander Röth","doi":"10.1007/s00277-025-06449-0","DOIUrl":"https://doi.org/10.1007/s00277-025-06449-0","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Good response to oxymetholone in adult aplastic anemia.","authors":"Jindaratn Chaipokam, Ponlapat Rojnuckarin","doi":"10.1007/s00277-025-06460-5","DOIUrl":"https://doi.org/10.1007/s00277-025-06460-5","url":null,"abstract":"<p><p>In Thailand, stem cell transplantation and horse antithymocyte globulin (ATG) are not accessible for most adult aplastic anemia (AA) patients. Alternative therapies are required. We conducted a cohort study of 110 adult AA patients treated with oxymetholone alone for at least 30 days from 2013 to 2023. Response at month 6 and prognostic factors were evaluated. The mean age was 63.4 years old and 58.2% were female. Severe and very severe AA (SAA/VSAA) comprised 64.5% and 3.6%, respectively. The initial oxymetholone daily dose was 150 mg in 66.4%. The overall response was 56.4% (50.7% for SAA/VSAA), with a median time to transfusion independence of 11.8 weeks. Deaths were regarded as no response. Seventeen (17.9%) patients discontinued the treatment due to side effects, especially hepatitis (15/17). Androgenic side effects (55.5%) mostly occurred within the first month. Multivariate analysis identified that baseline reticulocyte count > 10 × 10⁹/L (adjusted odds ratio [OR] 7.3, 95% confidence interval [CI] (2.55-21.11), oily skin (OR 4.93, 95%CI 1.50-16.26) and acne (OR 9.78, 95%CI 2.11-45.28) occurring within 2 months were predictive for responses. The SKAR scoring system using these three factors showed an area under the ROC curve of 0.87 (95%CI 0.80-0.92). The 5-year overall survival rate was 77.4%. Poor performance status (p < 0.001) and response status (p < 0.001) significantly impacted mortality. Responding patients demonstrated 94.5% 5-year survival. In conclusion, androgen is a useful treatment option for AA in Thailand. The score based on reticulocytes and androgenic effects could predict the response and potentially help decision-making.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CDKN1A as a potential target for Eltrombopag treatment in ITP and its regulation of the communication between macrophages and transitional B cells in ITP.","authors":"Shixuan Wang, Mankai Ju, Fancong Kong, Yuhuan Jiang, Yechao Tu, Jingyun Zou, Zhiming Zou, Genmei Tan, Fei Li","doi":"10.1007/s00277-025-06436-5","DOIUrl":"https://doi.org/10.1007/s00277-025-06436-5","url":null,"abstract":"<p><p>This study aimed to identify novel biomarkers associated with Eltrombopag response in patients with immune thrombocytopenia (ITP) and to investigate the role of macrophage and transitional B cells in ITP pathogenesis. Differentially expressed genes were identified using the GSE112278 dataset, followed by weighted gene co-expression network analysis (WGCNA) to screen hub genes. Single-cell RNA-seq data from GSE196676 were analyzed using the Seurat package to assess immune cell composition, gene expression, and cell-cell communication. CDKN1A expression was experimentally modulated in RAW264.7 macrophages via siRNA knockdown or plasmid overexpression. Phagocytic function was assessed using CFDA-labeled mouse platelets and F4/80 immunofluorescence staining. Molecular docking was conducted to evaluate the interaction between Eltrombopag and CDKN1A. Through intersection analysis, we identified CDKN1A as a key gene influencing the response of ITP patients to Eltrombopag treatment. Single-cell data analysis revealed a significant increase in the proportion of macrophages in ITP patients, accompanied by downregulation of CDKN1A expression in these macrophages, which was closely associated with macrophage activation and enhanced phagocytic capacity. Functional experiments confirmed that CDKN1A knockdown promoted, while overexpression inhibited, macrophage phagocytosis of platelets. Additionally, cell communication analysis demonstrated that macrophages in ITP patients interact with transitional B cells via the TGFβ signaling pathway. Further analysis revealed that a subset of macrophages performs effector functions by differentiating into specialized subtypes that function independently, without direct interaction with other immune cells. Our study identified CDKN1A as a key regulator of Eltrombopag's effectiveness in treating ITP. CDKN1A expression was reduced in macrophages of ITP patients and that it interacted with transitional B cells through the TGFβ signaling pathway to promote disease progression. These findings offer new insights into the pathogenic mechanisms of ITP and suggest CDKN1A as a potential therapeutic target for future interventions.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide conditioning in patients with central nervous system lymphoma: a phase II study.","authors":"Dong Hyun Kim, Taekeun Park, Junshik Hong, Dong-Yeop Shin, Inho Kim, Sung-Soo Yoon, Ja Min Byun, Youngil Koh","doi":"10.1007/s00277-025-06405-y","DOIUrl":"https://doi.org/10.1007/s00277-025-06405-y","url":null,"abstract":"<p><p>The prognosis of central nervous system lymphoma (CNSL) remains poor, and attempts have been made to improve outcomes through autologous stem cell transplantation (ASCT) with thiotepa-based conditioning. We aimed to assess the outcomes of thiotepa/busulfan/cyclophosphamide (TBC) followed by ASCT in CNSL. An investigator-initiated, single-arm, phase II trial was conducted to evaluate the efficacy and safety of TBC/ASCT (NCT06625359). The conditioning dose was adjusted based on age and performance status (9-day or 8-day regimen). As this trial was terminated early after enrolling 17 patients, a retrospective cohort of CNSL treated with the same protocol was included. In total, 44 patients were included in the study and classified into 8-day and 9-day groups according to the TBC regimen received. In total, 25 patients (56.8%) had primary CNSL, and 19 patients (43.2%) received the 9-day regimens. Following ASCT, 33 patients (75.0%) achieved an objective response (32 complete response and 1 partial response). The 3-year progression-free survival (46.5% vs. 52.6%, P = 0.49) and overall survival (60.5% vs. 73.7%, P = 0.77) for 8-day and 9-day groups were comparable. The 1-year cumulative incidence of non-relapse mortality in the 8-day group showed a trend toward decrease compared to that in the 9-day group (4.6% vs. 21.1%, P = 0.073). Our study demonstrates the efficacy of TBC/ASCT in CNSL in the Asian population. The conventional busulfan dose (9-day regimen) may be associated with higher toxicity, suggesting the potential need for a modified TBC regimen in Asian populations. Further studies are needed to identify the optimal thiotepa-based conditioning in CNSL.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basophilia and eosinophilia in polycythemia vera and essential thrombocythemia: clinical, genotype, and prognostic correlates.","authors":"Priyansh Faldu, Muhammad Yousuf, Maymona Abdelmagid, Sarah Dingli, Kebede Begna, Cinthya J Zepeda Mendoza, Kaaren K Reichard, Rong He, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi","doi":"10.1007/s00277-025-06422-x","DOIUrl":"https://doi.org/10.1007/s00277-025-06422-x","url":null,"abstract":"<p><p>The current retrospective study evaluated clinical, genetic, and prognostic correlates of increased absolute basophil (ABC) and eosinophil (AEC) counts in polycythemia vera (PV; N = 475) and essential thrombocythemia (ET; N = 658). Median (range) ABC and AEC were 0.1 (0-3.2) and 0.3 (0-6.5) x 10⁹/L in PV and 0.07 (0-0.8) and 0.2 (0-1.4) x 10⁹/L in ET. In PV, ABC ≥ 0.1 × 10⁹/L was associated with palpable splenomegaly and increased AEC, leukocyte count, and platelet count while AEC ≥ 0.5 × 10⁹/L was associated with increased ABC and leukocyte count. In ET, ABC ≥ 0.1 × 10⁹/L was associated with increased AEC, leukocyte count, platelet count, and cardiovascular risk factors while AEC ≥ 0.5 × 10⁹/L correlated with ABC and increased leukocyte count; genetic associations were seen only in ET and included ABC ≥ 0.1 × 10⁹/L with triple-negative driver mutation status (p = 0.03). In PV, AEC did not correlate with overall (OS), leukemia-free (LFS), myelofibrosis-free (MFFS), arterial thrombosis-free (ATFS), or venous thrombosis-free (VTFS) survival; by contrast, ABC ≥ 0.1 × 10⁹/L was associated with longer ATFS (p = 0.03) while ABC ≥ 0.3 × 10⁹/L was associated with inferior LFS (p < 0.01) and MFFS (p < 0.01); the associations with LFS and MFFS were sustained during multivariable analysis. In ET, both ABC ≥ 0.1 × 10⁹/L and AEC ≥ 0.5 × 10⁹/L were independently associated with inferior OS but impact on LFS, MFFS, ATFS, or VTFS was not apparent. The results from the current study warrant additional studies to clarify the potential association between basophilia in PV and disease transformation into acute myeloid leukemia and myelofibrosis.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of Glofitamab in patients with R/R DLBCL in real life setting- a retrospective study.","authors":"Ronit Gurion, Dmitri Guz, Meirav Kedmi, Chava Perry, Irit Avivi, Netanel A Horowitz, Uri Abadi, Anat Gafter-Gvili, Pia Raanani, Neta Goldschmidt, Boaz Nachmias, Shlomzion Aumann","doi":"10.1007/s00277-025-06438-3","DOIUrl":"https://doi.org/10.1007/s00277-025-06438-3","url":null,"abstract":"<p><p>Glofitamab, a CD20-directed CD3 T-cell engager, was recently FDA-approved after demonstrating a 52% overall response rate (ORR) and a 39% complete response (CR) rate in heavily pretreated diffuse large B-cell lymphoma (DLBCL) patients. However, real-world data on its efficacy and safety remain limited. This study evaluated glofitamab's performance in clinical practice. We conducted a retrospective multicenter study of adults with relapsed/refractory (R/R) DLBCL treated via a national compassionate use program. Patients received at least one dose of glofitamab after failing ≥ 2 prior therapies. Recruitment spanned September 2020-January 2023. Outcomes included ORR, CR (per Lugano criteria), progression-free survival (PFS), and overall survival (OS). Adverse events were classified per ASTCT 2019 criteria, and risk factors for PFS and OS were assessed via logistic regression. Thirty-five patients from six Israeli centers were included (median age: 67 years; 66% male). The median number of prior therapies was 5, with 43% being primary refractory and 91% post-CAR-T therapy. ORR was 34%, with 14% achieving CR. Median PFS and OS were 2 and 4 months, respectively. Treatment was prematurely discontinued in 86%, mainly due to disease progression (46%) and to infections in responding patients (17%). Male sex was a significant risk factor for poor PFS and OS. In this real-world cohort, glofitamab's efficacy was lower than in clinical trials, likely due to a more heavily pretreated population. However, its manageable toxicity supports its potential role in r/r DLBCL treatment.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-dose romiplostim for donor-type aplasia.","authors":"Kohei Hosokawa, Tatsuya Imi, Takafumi Yokota, Yuma Tada, Hiroyuki Maruyama, Naomi Sugimori, Ken Ishiyama, Hirohito Yamazaki, Toshihiro Miyamoto, Shinji Nakao","doi":"10.1007/s00277-025-06448-1","DOIUrl":"https://doi.org/10.1007/s00277-025-06448-1","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility analysis of metabolic parameters based on baseline ¹⁸F-FDG PET/CT to predict heterogeneity and recurrence of diffuse large B-cell lymphoma.","authors":"Fan Ge, Tingting Wu, Xinyue Yang, Mengye Peng, Chen Yang, Kezheng Wang","doi":"10.1007/s00277-025-06409-8","DOIUrl":"https://doi.org/10.1007/s00277-025-06409-8","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the predictive value of intra-tumoral ¹⁸F-FDG metabolic heterogeneity in patients with diffuse large B cell lymphoma (DLBCL) in terms of survival.</p><p><strong>Methods: </strong>We retrospectively included 245 patients with DLBCL who underwent ¹⁸F-FDG PET/CT prior to treatment and analyzed using total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) as metabolic volume parameters. The linear regression slopes of TMTV and TLG were calculated according to different percentages of SUV thresholds (i.e., 40%, 50%, 60%, 70%, and 80%), respectively, defined as Heterogeneity Factor-1 (HF1) and Heterogeneity Factor-2 (HF2). These indices of heterogeneity were used to predict progression-free survival (PFS). Based on the results of the Cox proportional hazards model, we constructed a multi-parameter prediction model and evaluated the model in the training and validation cohorts by calibration curve, consistency index (C-index) and decision curve analysis (DCA).</p><p><strong>Results: </strong>Clinicopathological and PET/CT data from 245 patients were reviewed. 153 patients (62.4%) experienced relapse after treatment. Comparing relapsed and non-relapse patients, all ¹⁸F-FDG PET/CT parameters and heterogeneity index showed significant differences. There were significant differences in survival risk stratification according to HF1 and HF2 cut-off classifications (P < 0.0001). In multivariate Cox regression analysis, SUVmax (P < 0.0001), TLG (P < 0.0001), HF1 (P = 0.004), and HF2 (P < 0.0001) showed significant results. Among the clinicopathological parameters, IPI (P = 0.027) and Size (P < 0.0001) were selected as important parameters.</p><p><strong>Conclusions: </strong>HF1 and HF2 obtained by the linear regression slope of MTV and TLG may be a novel and useful prognostic marker in DLBCL, which can achieve survival-risk stratification of patients. In addition, multiparametric models have the potential to effectively predict the risk of recurrence in patients.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}